Subject: FW: REMDESIVIR SOLIDARITY TRIALS NEGATIVE REPORTS
From: Archil Dzuliashvili <[email-masked]>
To: "[email-masked]" <[email-masked]>
Date: Sat, 17 Oct 2020 14:00:28 +0000

From: Vinay Dixit [mailto:[email-masked]]

Sent: Saturday, October 17, 2020 7:22 PM

To: Archil Dzuliashvili

Subject: FW: REMDESIVIR SOLIDARITY TRIALS NEGATIVE REPORTS

Dear Respected Sir,

Kindly find latest information on Remdesivir SOLIDARITY TRIALS for your kind perusal.

Regards,

Vinay

The article reports the interim mortality results of the SOLIDAIRY trial for the original 4 drugs, and this not the final report of the study. More so, the report is
not certified by peer review. There is lot of heterogeneity as the trial was conducted in 405 hospitals in 30 countries, and also in terms of standard of care. Hydroxychloroquine and Lopinavir were discontinued for futility on June 18 and July 4, 2020,
respectively; Interferon is ceasing on October 16.

In Solidarity trial, Remdesivir showed a RR=0.95 towards Death rate ratios and will continue to enrol patients to
further evaluate the small benefit. Combining data appropriately from all 4 trials as mentioned in the same article pertaining to the meta-analysis of mortality
(Remdesivir Meta-analysis – Table 1 below), the Remdesivir vs control death rate ratio
(RR) is 0.91 (95% CI 0.79-1.05), showing a small benefit with Remdesivir.

Of the 4 drugs earlier planned, Remdesivir is the only drug continuing in the Solidarity trial, and which is still recruiting about 2000 patients per month, and efficient factorial designs will allow it to assess further treatments,
such as immune-modulators and specific anti-SARSCov-2 monoclonal antibodies.

Table 1. Remdesivir vs control – Meta-analysis of mortality in trials of random allocation of hospitalised COVID-19 patients to Remdesivir or the same treatment
without it

Best regards,

Dr. Shyam Akku

Confidentiality Notice:

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity
named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error,
please delete the message
and any attachments
from your Inbox.